Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The Novel X-Ray Visible Zein-Based Non-adhesive Precipitating Liquid Embolic HEIE1_2017: An Exploratory Study.

Vollherbst DF, Do TD, Jugold M, Eichwald V, Macher-Göppinger S, Pereira PL, Bendszus M, Möhlenbruch MA, Richter GM, Kauczor HU, Sommer CM.

Cardiovasc Intervent Radiol. 2019 Jun;42(6):905-914. doi: 10.1007/s00270-019-02179-9. Epub 2019 Feb 13.

PMID:
30761410
2.

Inherently Radiopaque Narrow-Size-Calibrated Microspheres: Proof of Principle in a Pig Embolization Model.

Sommer CM, Harms A, Do TD, Gockner TL, Kriegsmann M, Schlett CL, Holzer K, Vollherbst D, Warth A, Pereira PL, Eichwald V, Jugold M, Kauczor HU, Flechsig P.

Cardiovasc Intervent Radiol. 2018 Sep;41(9):1404-1411. doi: 10.1007/s00270-018-1986-0. Epub 2018 Jun 1.

PMID:
29858644
3.

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16.

4.

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A.

Acta Neuropathol. 2017 Apr;133(4):629-644. doi: 10.1007/s00401-017-1677-y. Epub 2017 Jan 25.

PMID:
28124097
5.

Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.

Lemke D, Pledl HW, Zorn M, Jugold M, Green E, Blaes J, Löw S, Hertenstein A, Ott M, Sahm F, Steffen AC, Weiler M, Winkler F, Platten M, Dong Z, Wick W.

Oncotarget. 2016 Aug 30;7(35):56713-56725. doi: 10.18632/oncotarget.10723.

6.

Establishment of a patient-derived orthotopic osteosarcoma mouse model.

Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, Lehner B, Renker E, Jugold M, Eichwald V, Weichert W, Huber PE, Kulozik AE.

J Transl Med. 2015 Apr 30;13:136. doi: 10.1186/s12967-015-0497-x.

7.

Cell-based therapy by implanted human bone marrow-derived mononuclear cells improved bone healing of large bone defects in rats.

Seebach C, Henrich D, Schaible A, Relja B, Jugold M, Bönig H, Marzi I.

Tissue Eng Part A. 2015 May;21(9-10):1565-78. doi: 10.1089/ten.TEA.2014.0410. Epub 2015 Apr 13.

PMID:
25693739
8.

Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.

Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, Augustin HG.

Cancer Cell. 2014 Dec 8;26(6):880-895. doi: 10.1016/j.ccell.2014.11.005.

9.

NDRG1 prognosticates the natural course of disease in WHO grade II glioma.

Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W.

J Neurooncol. 2014 Mar;117(1):25-32. doi: 10.1007/s11060-013-1357-2. Epub 2014 Jan 7.

10.

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):409-14. doi: 10.1073/pnas.1314469111. Epub 2013 Dec 23.

11.

BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.

Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AHC, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Sturm D, Witt H, Chan TA, Herold-Mende C, Kemkemer R, König R, Schmidt K, Hull WE, Pfister SM, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger G, Lichter P, Radlwimmer B.

Nat Med. 2013 Jul;19(7):901-908. doi: 10.1038/nm.3217. Epub 2013 Jun 23.

12.

The fibrillin-1 hypomorphic mgR/mgR murine model of Marfan syndrome shows severe elastolysis in all segments of the aorta.

Schwill S, Seppelt P, Grünhagen J, Ott CE, Jugold M, Ruhparwar A, Robinson PN, Karck M, Kallenbach K.

J Vasc Surg. 2013 Jun;57(6):1628-36, 1636.e1-3. doi: 10.1016/j.jvs.2012.10.007. Epub 2013 Jan 4.

13.

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.

Weiler M, Pfenning PN, Thiepold AL, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M, Platten M, Wick W.

Oncogene. 2013 Feb 28;32(9):1099-109. doi: 10.1038/onc.2012.137. Epub 2012 May 7.

14.

KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas.

Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, Pfenning PN, Waha A, Wohlleber D, Brockschmidt FF, Jugold M, Hoischen A, Kalla C, Waha A, Seifert G, Knolle PA, Latz E, Hans VH, Wick W, Pfeifer A, Angel P, Weber RG.

Brain. 2012 Apr;135(Pt 4):1027-41. doi: 10.1093/brain/aws045. Epub 2012 Mar 16.

PMID:
22427331
15.

MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma.

Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, Kool M, Northcott PA, Jugold M, Bazhin AV, Eichmüller SB, Kulozik AE, Pscherer A, Benner A, Taylor MD, Pomeroy SL, Kemkemer R, Witt O, Korshunov A, Lichter P, Pfister SM.

Acta Neuropathol. 2012 Apr;123(4):529-38. doi: 10.1007/s00401-011-0924-x. Epub 2011 Dec 2.

PMID:
22134538
16.

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M.

Nature. 2011 Oct 5;478(7368):197-203. doi: 10.1038/nature10491.

17.

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.

Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O.

Acta Neuropathol. 2011 Nov;122(5):637-50. doi: 10.1007/s00401-011-0866-3. Epub 2011 Aug 24.

18.

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice.

Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DT, Witt O, Heiland S, Bendszus M, Holland EC, Pfister S, Lichter P.

J Clin Invest. 2011 Apr;121(4):1344-8. doi: 10.1172/JCI44656. Epub 2011 Mar 14.

19.

Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

Hakroush S, Moeller MJ, Theilig F, Kaissling B, Sijmonsma TP, Jugold M, Akeson AL, Traykova-Brauch M, Hosser H, Hähnel B, Gröne HJ, Koesters R, Kriz W.

Am J Pathol. 2009 Nov;175(5):1883-95. doi: 10.2353/ajpath.2009.080792. Epub 2009 Oct 15.

20.

Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2.

Reiss Y, Knedla A, Tal AO, Schmidt MHH, Jugold M, Kiessling F, Burger AM, Wolburg H, Deutsch U, Plate KH.

J Pathol. 2009 Mar;217(4):571-80. doi: 10.1002/path.2484.

PMID:
19116989
21.

Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis.

Carmona G, Göttig S, Orlandi A, Scheele J, Bäuerle T, Jugold M, Kiessling F, Henschler R, Zeiher AM, Dimmeler S, Chavakis E.

Blood. 2009 Jan 8;113(2):488-97. doi: 10.1182/blood-2008-02-138438. Epub 2008 Sep 19.

PMID:
18805968
22.

Flt-1 signaling in macrophages promotes glioma growth in vivo.

Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, Machein MR.

Cancer Res. 2008 Sep 15;68(18):7342-51. doi: 10.1158/0008-5472.CAN-07-6241.

23.

Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, Arnold B, Ganss R.

Nature. 2008 May 15;453(7193):410-4. doi: 10.1038/nature06868. Epub 2008 Apr 16.

PMID:
18418378
24.

Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice.

Jugold M, Palmowski M, Huppert J, Woenne EC, Mueller MM, Semmler W, Kiessling F.

Eur Radiol. 2008 Apr;18(4):753-8. Epub 2007 Dec 15.

PMID:
18084768
25.

Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging.

Kiessling F, Jugold M, Woenne EC, Brix G.

Eur Radiol. 2007 Aug;17(8):2136-48. Epub 2007 Feb 17. Review.

PMID:
17308924
26.

Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.

Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F.

Cancer Res. 2007 Feb 15;67(4):1555-62.

Supplemental Content

Loading ...
Support Center